India Drug M&As Seen Continuing For Three Years Until MNCs Dominate
This article was originally published in PharmAsia News
Executive Summary
Merger and acquisition fever in India is expected to continue for another two or three years, leading eventually to multinational drug makers having more clout than domestic firms. Analysts and pharma experts believe the MNCs will gain strength vis-à-vis domestic makers on a steady basis until the shift of dominance begins in another three years. M&A activity among Indian drug makers has grown since the first one, the 2006 acquisition of Matrix Laboratories by U.S.-based Mylan Laboratories. Currently, Indian firms still dominate, with 75 percent of the local market share, but analysts see that percentage slowly decreasing. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.